Editorials

Mirror, Mirror, on the Wall, Which Is the Most Effective Biologic of All? A. Deodhar ........................................... 449
Toward a Multibiomarker Panel to Optimize Outcome and Predict Response in Juvenile Idiopathic Arthritis
J. Vojinovic ................................................................. 451
A Changing Landscape of Gout: Comorbidity Matters
C.F. Kuo ................................................................. 454

Rheumatoid Arthritis

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in RA
Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with RA
HLA-DRB1 Analysis Identified a Genetically Unique Subset within RA and Distinct Genetic Background of Rheumatoid Factor Levels from Anticyclic Citrullinated Peptide Antibodies
R. Hiwa, K. Ikari, K. Ohmura, et al ........................................ 470

Ankylosing Spondylitis

Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in AS: A Systematic Review and Bayesian Network Metaanalysis
R. Wang, A. Dasgupta, M.M. Ward ........................................ 481
Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice
C. Pereira-Gillon, M. Marot, I. Griffoul-Espitalier, L. Andrés, P. Goupille, C. Salliot ........................................ 491
Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study

Systemic Lupus Erythematosus

The Crescentic Implication of Renal Outcomes in Proliferative Lupus Nephritis
F. Cai, F. Han, H. Wang, et al ........................................ 513

Vasculitis

Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study
A. Hara, T. Wada, K. Sada, et al, for the Research Committee on Intractable Vasculitides, and the Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline ........................................ 521
Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
P. Eriksson, M. Segelmark, O. Hallböök ........................................ 529

Myositis

Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study
H. Alexanderson, M. Regardt, C. Ottosson, et al ............................. 538

Pediatric Rheumatology

S100A12 Is Associated with Response to Therapy in JIA
F. Gohar, J. Anink, H. Moncrieffe, et al ........................................ 547

Osteoarthritis

Occupation, Physical Workload Factors, and Disability Retirement as a Result of Hip OA in Finland, 2005–2013
S. Solovieva, T. Kontio, E. Vikari-Juntura ........................................ 555

Free online via JRheum Full Release option

Contents continued on page xvi
Osteoarthritis/Rheumatoid Arthritis
Synoviocytes-derived Interleukin 35 Potentiates B Cell Response in Patients with OA and RA
N.W. Kam, D. Liu, Z. Cai, et al. ........................................... 563

Gout
The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years
M.M. Elfishawi, N. Zleik, Z. Krvigic, et al. ............................. 574

Images in Rheumatology
Ocular Involvement in Sarcoidosis
J.J. Raevis, N. Antonova, S. Agemy ............................... 580

Letters
Successful Lung Transplantation in a Case of Rapidly Progressive ILD Associated with Antimelanoma Differentiation-associated Gene 5 Antibodies
V. Leclair, A. Labirua, I.E. Lundberg ................................. 581

Causes of Hospital Mortality in Patients with RA and SLE in a University Hospital: 1998-2015 Analysis
D. Vega-Morales, I.J. Hernández-Galarza,
D.A. Galarza-Delgado .................................................. 583

Meetings in Rheumatology ........................................... x